Article
Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Feb 2009
Woo Sukyung, Gardner Erin R, Chen Xiaohong, Ockers Sandra B, Baum Caitlin E, Sissung Tristan M, Price Douglas K, Frye Robin, Piekarz Richard L, Bates Susan E, Figg William D
Abstract excerpt
PURPOSE: Romidepsin is a potent histone deacetylase inhibitor under clinical development. The objective of this study was to evaluate the effect of demographic, clinical, and pharmacogenetic covariates on the pharmacokinetics of romidepsin in patients with T-cell lymphoma. EXPERIMENTAL DESIGN: Ph...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
